Other Income	12 Months Ended
Apr. 30, 2020
Other Nonoperating Income Expense [Abstract]
Other Income	Note 12. Other Income As of April 30, 2020 and 2019, the Company had research and development tax credits receivable totaling $16.5 million and $11.3 million, respectively. This tax credit is related to a tax scheme for small and medium enterprises in the United Kingdom as well as an R&D expenditure credit system that allows the Company to file a claim for cash credit in proportion to the Company’s R&D expenditure for the year. This amount is included in other income, as it is a refundable credit that does not depend on the Company’s ongoing tax status or position. The Company recognized $9.5 million, $7.6 million and $4.4 million related to these programs in the years ended April 30, 2020, 2019 and 2018, respectively. In the year ended April 30, 2020, other income also included $0.3 million of realized gains from the sale of available for sale securities.

Other Income

12 Months Ended

Apr. 30, 2020

Other Nonoperating Income Expense [Abstract]

Note 12. Other Income

As of April 30, 2020 and 2019, the Company had research and development tax credits receivable totaling $16.5 million and $11.3 million, respectively. This tax credit is related to a tax scheme for small and medium enterprises in the United Kingdom as well as an R&D expenditure credit system that allows the Company to file a claim for cash credit in proportion to the Company’s R&D expenditure for the year. This amount is included in other income, as it is a refundable credit that does not depend on the Company’s ongoing tax status or position. The Company recognized $9.5 million, $7.6 million and $4.4 million related to these programs in the years ended April 30, 2020, 2019 and 2018, respectively. In the year ended April 30, 2020, other income also included $0.3 million of realized gains from the sale of available for sale securities.